Insmed (INSM) Tops Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall Street rallies, Dow closes at record on Iran talks optimism
- Fed's Williams says rate hikes possible if inflation persists
- Citi says buy these 3 chip stocks on pullback
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Deutsche Bank raises S&P 500 earnings estimates on the back of the solid Q2 beats
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
Insmed Reports First Quarter 2022 Financial Results and Provides Business Update
May 5, 2022 7:30 AM EDT--ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 32% Year Over Year Growth for the First Quarter of 2022 with Total Revenue of $53.1 Million--
--Seven Clinical Trials Underway; Enrollment on Track in Brensocatib Phase 3 ASPEN Study and ARIKAYCE Post-Marketing Studies (ARISE and ENCORE)--
--Company Reiterates Revenue Guidance of at Least 30% Growth in 2022 and Cash Runway into 2024 to Support Ongoing Programs--
BRIDGEWATER, N.J., May 5, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the... More
